Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has updated the reference to Seagen, now explicitly stating it as a wholly owned subsidiary of Pfizer, and has changed a date from March 12, 2025, to March 24, 2025.
    Difference
    3%
    Check dated 2025-03-25T13:57:23.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The date '2025-03-12' has been added, while '2024-11-13' has been removed from the page.
    Difference
    1.0%
    Check dated 2025-03-18T08:54:16.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T21:08:38.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    6%
    Check dated 2025-02-10T09:52:45.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T08:40:35.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T22:50:26.000Z thumbnail image

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.